<DOC>
	<DOCNO>NCT01869829</DOCNO>
	<brief_summary>The overarch objective ultimately develop new evidence-based treatment guideline invasive fungal infection child . To accomplish , protocol focus two specific aim : 1 ) Compare effectiveness echinocandin versus amphotericin B triazole antifungal therapy pediatric invasive candidiasis ; 2 ) Characterize incidence pediatric invasive candidiasis .</brief_summary>
	<brief_title>PEACE : Pediatric Antifungal Comparative Effectiveness</brief_title>
	<detailed_description>This study multicenter , national international , prospective observational comparative effectiveness study also employ case-control study design base prospectively identified case control , well general epidemiology database . The primary aim study compare effectiveness echinocandin versus amphotericin B triazole antifungal therapy pediatric invasive candidiasis . In order accomplish first aim , study utilize control comparative effectiveness study design . The primary effectiveness endpoint study aim 1 comparison global response 14 day antifungal therapy antifungal therapeutic class . The secondary effectiveness endpoint study aim 1 comparative effectiveness 1 ) global response antifungal therapy 35 day 2 ) all-cause mortality 35 day . The secondary aim characterize frequency pediatric candidiasis . For aim , investigator use descriptive statistic establish frequency hospital admission involve invasive candidiasis per total hospital admission total hospital day study period . The endpoint aim 2 describe incidence pediatric candidiasis relative pediatric admission .</detailed_description>
	<mesh_term>Candidiasis</mesh_term>
	<mesh_term>Candidiasis , Invasive</mesh_term>
	<mesh_term>Fluconazole</mesh_term>
	<mesh_term>Voriconazole</mesh_term>
	<mesh_term>Amphotericin B</mesh_term>
	<mesh_term>Liposomal amphotericin B</mesh_term>
	<mesh_term>Antifungal Agents</mesh_term>
	<mesh_term>Miconazole</mesh_term>
	<mesh_term>Micafungin</mesh_term>
	<mesh_term>Caspofungin</mesh_term>
	<criteria>1 . Males females age &gt; 120 day &lt; 18 year 2 . Incident case invasive candidiasis 3 . Parental/guardian permission ( informed consent , require ) appropriate , child assent ( require ) . 1 ) Any history prior Candida infection within previous 35 day ( These patient eligible analysis aim 1 eligible inclusion aim 2 )</criteria>
	<gender>All</gender>
	<minimum_age>120 Days</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Candida</keyword>
	<keyword>Pediatric</keyword>
	<keyword>Antifungal</keyword>
</DOC>